Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study.-Reference-Cited by-同舟云学术

Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:4005-4005
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Pryma Daniel¹,Chin Bennett²,Noto Richard³,Dillon Joseph⁴,Solnes Lilja⁵,White Theresa⁶,Stambler Nancy⁶,Lin Tess⁶,DiPippo Vincent A.⁶,Jensen Jessica Donato⁶,Mahmood Syed⁶,Wong Vivien⁶,Jimenez Camilo⁷

Affiliation:

1. Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;

2. Duke University, Durham, NC;

3. Rhode Island Hospital, Providence, RI;

4. University of Iowa, Iowa City, IA;

5. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD;

6. Progenics Pharmaceuticals, Inc., New York, NY;

7. The University of Texas MD Anderson Cancer Center, Houston, TX;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.4005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect;Molecular Pharmaceutics;2022-06-02

2. Synthesis of the Guanidine Derivative: N-{[(7-(4,5-Dihydro-1H-imidazol-2-yl)-2-(p-tolyl)-6,7-dihydro-2H-imidazo[2,1-c][1,2,4]triazol-3(5H)-ylidene)amino](phenylamino)methylene}benzamide;Molbank;2021-07-06

3. ‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’;Clinical Endocrinology;2019-10-13